---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000028"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:13:40.105874+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q1 2025 net loss $5.1M; cash $31.1M; cadisegliatin Phase 3 data expected 2H 2026

## Summary
- Net loss attributable to shareholders was $5.1M ($0.77 per share) vs $4.9M ($1.17 per share) in Q1 2024.
- Cash at March 31, 2025: $31.1M, down from $36.7M at December 31, 2024.
- Revenue was $0 compared to $1.0M in the prior-year period.
- Phase 3 CATT1 trial for cadisegliatin shortened from 12 to 6 months; topline data expected in 2H 2026.
- R&D expenses $2.8M, G&A $3.7M; operating loss of $6.5M.

## SEC filing metadata
- accession: 0001641489-25-000028
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/0001641489-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000028/vtvt-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000028
- JSON: https://secwatch.observer/filing/0001641489-25-000028.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.